However, these studies have also shown that the activation of Nrf2 or suppression of NF-κB and/or SREBP1/2 alleviated hepatic steatosis and protected against the development of NASH and hepatic fibrosis in experimental animals. This evidence concerns the gene NFKB1 and fatty liver disease.